Compare Incyte Corporation (INCY) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs S&P Global Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while S&P Global Inc trades at $409 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 4.9× Incyte Corporation's market cap, and S&P Global Inc pays a 0.95% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SPGI | |
|---|---|---|
Market Cap | $24.54B | $120.48B |
Sector | Health | Financials |
52-Week High | $129.93 | $534.79 |
52-Week Low | $81.61 | $370.42 |
Enterprise Value | $20.04B | $131.97B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
S&P Global (SPGI) trades at $410.26, down 0.17% on the day, with a bearish technical signal from moving averages and ADX. The company reported strong Q2 2026 earnings of $4.83 per share, beating estimates, and maintains robust profitability with a 30.54% net income margin. Recent news highlights expansion in AI and data collaborations, including integration with Microsoft 365 Copilot.
The outlook remains positive with 86% analyst buy ratings and a $523.20 consensus price target, implying significant upside. Risks include competitive pressures and reliance on financial market health. Revenue growth and strategic partnerships support long-term value, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
